Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metastatic Urothelial Carcinoma
Shots:
- The P-1b/2 KEYNOTE-146/Study 111 trial involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg IV q3w) in patients with NSCLC- Advanced melanoma & urothelial cancer
- P1b/2 KEYNOTE-146/Study 111 results: NSCLC: ORR 33.3%- mPFS 5.9 mos.- mDOR 10.9 mos.; Advanced melanoma: ORR 47.6%- mPFS 5.5 mos.- mDOR (12.5 mos.); Metastatic Urothelial Carcinoma: ORR 25%- mPFS 5.4 mos.- Collectively was well tolerated
- Lenvima PO is a mAb- kinase inhibitor of VEGF receptors- and is approved for refractory thyroid cancer in 50 countries. In Mar 2018- Merck & Eisai collaborated to co-develop Lenvima globally
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
